Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document ...

In summary, dupilumab provides a targeted and generally well-tolerated treatment option for severe asthma. It is approved as add-on maintenance therapy for patients aged ≥6 years with ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

The number of adults with life-threatening food allergies is on the rise. When researchers at Northwestern University’s ...